PCSK9 inhibitors attenuates arterial stiffness in patients with acute coronary syndrome

PCSK9 Inhibitors Reduce Arterial Stiffness in Acute Coronary Syndrome

  • Liang Wang Shanghai East Hospital, School of Medicine, Tongji University
  • Ruijie Wang Shanghai East Hospital, School of Medicine, Tongji University
  • Tiantian Jiao Shanghai East Hospital, School of Medicine, Tongji University
  • Linghao Xu Shanghai East Hospital, School of Medicine, Tongji University
  • Endong Ji Shanghai East Hospital, School of Medicine, Tongji University
  • Yuanzhen Jiang Shanghai East Hospital, School of Medicine, Tongji University
  • Yuanqi Wang Shanghai East Hospital, School of Medicine, Tongji University
  • Yehong Liu Shanghai East Hospital, School of Medicine, Tongji University
  • Jiming Li Department of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University
DOI: https://doi.org/10.5937/jomb0-54773
Keywords: PCSK9 inhibitors, Acute coronary syndrome, Arterial stiffness

Abstract


Background: This study aimed to evaluate the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on arterial stiffness in patients with acute coronary syndrome and atherosclerosis, an area that has not been extensively explored.

Methods: Patients were randomly divided into two groups: one group received statin therapy combined with PCSK9 inhibitors (Evolocumab or Alirocumab), while the other group received statins alone. Indicators of lipid metabolism and arterial stiffness were measured at baseline, 1 month, and 6 months after treatment initiation.

Results: After 1 month, the group treated with statins and PCSK9 inhibitors showed significantly greater reductions in LVEF, NTP, TC, TG, LDL, and Lp(a) levels compared to the statin-only group. By the 6-month follow-up, pulse wave velocity showed marked improvement (p < 0.05), and ankle-brachial index was also significantly reduced in the combination treatment group (p < 0.05). No significant differences were observed between Evolocumab and Alirocumab (p > 0.05).

Conclusions: The findings suggest that PCSK9 inhibitors not only improve lipid metabolism but also reduce arterial stiffness, supporting their use in treating vascular disorders in patients with acute coronary syndrome and atherosclerosis.

References

1. Du L, Cheng Z, Zhang Y, Li Y, Mei D. The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis. Eur J Prev Cardiol 2017; 24(9): 962-70.
2. Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJ, Kastelein JJ, et al. Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. Circulation 2016; 134(19): 1419-29.
3. Held C, White HD, Stewart R, Budaj A, Cannon CP, Hochman JS, et al. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc 2017; 6(10):
4. Ridker PM. Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk: JACC Review Topic of the Week. J Am Coll Cardiol 2018; 72(25): 3320-31.
5. Scicali R, Di Pino A, Urbano F, Ferrara V, Marchisello S, Di Mauro S, et al. Analysis of S100A12 plasma levels in hyperlipidemic subjects with or without familial hypercholesterolemia. Acta Diabetol 2019; 56(8): 899-906.
6. Ikonomidis I, Makavos G, Lekakis J. Arterial stiffness and coronary artery disease. Curr Opin Cardiol 2015; 30(4): 422-31.
7. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscl Throm Vas 2005; 25(5): 932-43.
8. Kim HL, Kim SH. Pulse Wave Velocity in Atherosclerosis. Front Cardiovasc Med 2019; 6: 41.
9. Valencia-Hernandez CA, Lindbohm JV, Shipley MJ, Wilkinson IB, McEniery CM, Ahmadi-Abhari S, et al. Aortic Pulse Wave Velocity as Adjunct Risk Marker for Assessing Cardiovascular Disease Risk: Prospective Study. Hypertension 2022; 79(4): 836-43.
10. Kubozono T, Miyata M, Kawasoe S, Ojima S, Yoshifuku S, Miyahara H, et al. High Pulse Wave Velocity Has a Strong Impact on Early Carotid Atherosclerosis in a Japanese General Male Population. Circ J 2017; 81(3): 310-5.
11. Lekuona I. PCSK9 Inhibitors: From Innovation to Sustainable Clinical Application. Rev Esp Cardiol (Engl Ed) 2018; 71(12): 996-8.
12. Mandraffino G, Scicali R, Rodriguez-Carrio J, Savarino F, Mamone F, Scuruchi M, et al. Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience. J Clin Lipidol 2020; 14(2): 231-40.
13. Galema-Boers A, Lenzen MJ, Sijbrands EJ, Roeters VLJ. Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience. J Clin Lipidol 2017; 11(3): 674-81.
14. Yang Y, Fan F, Kou M, Yang Y, Cheng G, Jia J, et al. Brachial-Ankle Pulse Wave Velocity is Associated with the Risk of New Carotid Plaque Formation: Data from a Chinese Community-based Cohort. Sci Rep-Uk 2018; 8(1): 7037.
15. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. P Natl Acad Sci Usa 2003; 100(3): 928-33.
16. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New Engl J Med 2017; 376(18): 1713-22.
17. Han Y, Chen J, Chopra VK, Zhang S, Su G, Ma C, et al. ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand. J Clin Lipidol 2020; 14(1): 98-108.
18. Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscl Throm Vas 2010; 30(12): 2311-6.
19. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Jama-J Am Med Assoc 2009; 302(4): 412-23.
20. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 2013; 61(11): 1146-56.
21. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. New Engl J Med 2009; 361(26): 2518-28.
22. Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxid Med Cell Longev 2017; 2017: 1273042.
23. Lage J, Bortolotto AL, Scanavacca MI, Bortolotto LA, Darrieux F. Arterial stiffness and atrial fibrillation: A review. Clinics 2022; 77: 100014.
24. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006; 113(5): 657-63.
25. Wang X, Keith JJ, Struthers AD, Feuerstein GZ. Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk. Cardiovasc Ther 2008; 26(3): 214-23.
26. Liu L, Sun H, Nie F, Hu X. Prognostic Value of Abnormal Ankle-Brachial Index in Patients With Coronary Artery Disease: A Meta-Analysis. Angiology 2020; 71(6): 491-7.
27. Lee JY, Lee SJ, Lee SW, Kim TO, Yang Y, Jeong YJ, et al. Long-Term (7-Year) Clinical Implications of Newly Unveiled Asymptomatic Abnormal Ankle-Brachial Index in Patients With Coronary Artery Disease. J Am Heart Assoc 2021; 10(20): e021587.
28. Scicali R, Di Pino A, Ferrara V, Rabuazzo AM, Purrello F, Piro S. Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting. Acta Diabetol 2021; 58(7): 949-57.
29. Toscano A, Cinquegrani M, Scuruchi M, Di Pino A, Piro S, Ferrara V, et al. PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy. Biomolecules 2022; 12(4):
30. Scicali R, Mandraffino G, Scuruchi M, Lo GA, Di Pino A, Ferrara V, et al. Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units. Biomedicines 2022; 10(7):
Published
2025/02/05
Issue
Vol. 44 No. 3 (2025): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2025 Liang Wang, Ruijie Wang, Tiantian Jiao, Linghao Xu, Endong Ji, Yuanzhen Jiang, Yuanqi Wang, Yehong Liu, Jiming Li

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.